NEW YORK (GenomeWeb) – Roughly two years after it agreed to pay $518 million for Devgen and its portfolio of agricultural RNAi technologies, Syngenta announced this month that it is collaborating with Australian startup Nexgen to develop virus-resistant crop plants through microRNA targeting.
Australian expressed RNAi firm Benitec Biopharma provided an update on its research and development activities late last month, reporting that it remains on track to move its lead drug candidate, the hepatitis C therapy TT-034, into the clinic as early as this month.
Medical Diagnostics Laboratories has been awarded US Patent No. 8,206,930, "Compositions and methods for detecting Borrelia afzelii."
Melanie Feola, Martin Adelson, Eli Mordechai, and Lisa Novak are named as inventors on the patent.